Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of Evacetrapib in High-Risk Vascular Disease (ACCELERATE)

This study has been terminated.
(Study termination due to insufficient efficacy.)
Sponsor:
Collaborator:
The Cleveland Clinic
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01687998
First received: September 12, 2012
Last updated: December 12, 2016
Last verified: December 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: July 2016
  Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: August 13, 2016